Critical Limb Ischemia Market to Progress at a CAGR of 10.6% by 2030 | DelveInsight
07 Jun 2022
Gene TherapyInnovative DrugCell Therapy
The critical limb ischemia market is expected to expand with a rise in prevalence and the expected entry of emerging therapies into the 7MM markets.
LAS VEGAS, June 7, 2022 /PRNewswire/ -- DelveInsight's
critical limb ischemia market insights report includes a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2018 to 2030, segmented into 7MM (the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Key Takeaways from the Critical Limb Ischemia Market
According to DelveInsight estimates, the Critical Limb Ischemia market size in the 7MM was
USD 1,519 million in 2020.
As per analysis, the total critical limb ischemia diagnosed prevalent population in the 7MM was approximately
2 million in 2020.
Key critical limb ischemia companies such as
Boston Scientific Corporation, AnGes, Inc., Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Inc, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, Inc., New Beta Innovation Limited, BioGenCell Ltd., Abbott Medical Devices, and others are developing novel drugs and technologies/devices, which can be available in the critical limb ischemia market in the upcoming years.
The critical limb ischemia therapies/technologies/devices in the pipeline include
REX-001, Temsirolimus Adventitial Delivery, Collategene, ACP-01, Honedra (CLBS12), RJX (Rejuveinix), YQ23, BGC101, Esprit BTK Device
, and others.
The increase in the critical limb ischemia market size directly impacts the increasing prevalent population of critical limb ischemia patients in the 7MM.
Discover more about therapies that are set to grab major critical limb ischemia market share at
critical limb ischemia market landscape
Critical limb ischemia is a clinical syndrome characterized by ischemic pain at rest and tissue loss, such as nonhealing ulcers or gangrene, caused by lower limb peripheral arterial disease (PAD). Critical limb ischemia is the final stage of PAD, and macrovascular lesions cause a decrease in distal perfusion. This disease drastically impairs nutrient blood flow to tissues and microcirculation exchange.
Rutherford has traditionally characterized critical limb ischemia as rest pain (class 4), tissue loss (class 5), and gangrene (class 6). Rest discomfort is classified as class 3 in the Fontaine classification, and tissue loss or gangrene is classified as class 4 in the Fontaine classification. The threatened critical limb ischemia classification system was recently developed by the Society for Vascular Surgery Lower Extremity Guidelines Committee: Risk stratification based on wound, ischemia, and foot infection (WIfI).
The critical limb ischemia life expectancy is around 1.23 years for men and 2.7 years for women.
The most noticeable critical limb ischemia symptoms are ischemic rest pain — extreme pain in the legs and feet when a person is not moving or nonhealing sores on the feet or legs. Other critical limb ischemia symptoms include an absent or decreased pulse in the legs or feet, open sores, skin infections or nonhealing ulcers, toenail thickening, dry gangrene, shiny, smooth, dry skin of the legs or feet, and pain or numbness in the feet; other factors such as age, smoking, diabetes, high cholesterol, family history, etc. also contribute.
Physical examination and noninvasive hemodynamic testing (ankle-brachial index [ABI]/ankle pressure [AP], toe-brachial index [TBI]/toe pressure [TP], imaging of vascular anatomy, duplex ultrasound imaging [DUS], computed tomography angiography [CTA], and others) can be used for critical limb ischemia diagnosis.
Critical Limb Ischemia Epidemiology Segmentation
In 2020, approximately
2 million critical limb ischemia diagnosed prevalent population was affected in the 7MM.
Among EU5 countries, Germany had the highest critical limb ischemia diagnosed prevalence in 2020.
The
critical limb ischemia market report offers epidemiological analysis for the study period 2018–2030 in the 7MM segmented into:
Total diagnosed prevalent cases of critical limb ischemia
Age-specific diagnosed prevalent cases of critical limb ischemia
Severity-specific diagnosed prevalent cases of critical limb ischemia
Diagnosed prevalent cases of no-option critical limb ischemia
Download the report to understand which factors are driving critical limb ischemia epidemiology trends at
critical limb ischemia epidemiological insights
Critical Limb Ischemia Treatment Market
The basic aim of Critical Limb Ischemia treatment is pain relief, trophic lesion healing, avoiding high-level amputations, improving limb functionality and quality of life, and improving medium-term survival. These objectives call for an interdisciplinary approach.
Revascularization is the most common and effective critical limb ischemia treatment option. Other approaches include the
administration of analgesics, the treatment of infections, and the optimization of cardiac and pulmonary function. Patients with critical limb ischemia require monitoring and therapy for cardiovascular risk factors as much as any other patient with PAD. When revascularizing operations are not possible or have proven unsuccessful,
prostanoids are utilized. Cell and gene therapies are gaining popularity as critical limb ischemia treatments for patients ineligible for endovascular or surgical revascularization.
Several regeneration treatments, including angiogenic recombinant proteins, gene therapy, cell-based therapies (including stem or progenitor cells), and chemokines, have been studied in patients with PAD and nonrevascularizable critical limb ischemia.
Collategene (HGF plasmid) is the only approved critical limb ischemia treatment in Japan. The company also intends to penetrate the US critical limb ischemia market.
Furthermore, many cell therapies are being developed to target the population that is not appropriate for revascularization or has poor results following revascularization.
To know about more Critical Limb Ischemia management, visit at
critical limb ischemia guidelines
Critical Limb Ischemia Pipeline Therapies/Technologies/Devices and Key Companies
Temsirolimus Adventitial Delivery: Mercator MedSystems, Inc.
Collategene: Anges and Mitsubishi Tanabe Pharma
Honedra (CLBS12): Caladrius BiosciencesCaladrius Biosciences
RJX (Rejuveinix): Reven Pharmaceuticals, Inc.
Esprit BTK Device: Abbott Medical Devices
Critical Limb Ischemia Market Dynamics
The
rising prevalence of diabetes due to an aging global population will boost the critical limb ischemia treatment options, resulting in critical limb ischemia market growth. Moreover, companies are actively developing critical limb ischemia drugs to
address the disease's unmet requirements, despite the disease's low visibility and complexity.
Except in Japan, there are
no authorized pharmaceutical critical limb ischemia treatment alternatives, creating tremendous potential for investment and research for innovative drugs along with less competition. The present unmet need of the critical limb ischemia market is medications that are safer and more effective in providing an optimal cure. However, some factors restrain the critical limb ischemia market growth.
The disease is being
underdiagnosed and undertreated, resulting in greater morbidity, death, and costs. L
ack of awareness and other similar diseases challenge the critical limb ischemia market's growth.
Pricing and reimbursement rules that are strictly enforced also limit the growth of the critical limb ischemia market along with the failure of drugs in clinical development. Moreover, the
availability of surgical procedures may make it difficult for innovative treatments to get a foothold.
Scope of the
Market Report
Study Period: 2018–2030
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key
Companies: Boston Scientific Corporation
Key
Critical Limb Ischemia Therapies/Technologies/Devices: REX-001, Temsirolimus Adventitial Delivery, Collategene, ACP-01, Honedra (CLBS12), RJX (Rejuveinix), YQ23, BGC101, Esprit BTK Device, and others
Therapeutic Assessment: Critical Limb Ischemia current marketed and emerging therapies
Market Dynamics: Critical Limb Ischemia market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views,
Discover more about the future critical limb ischemia market share of treatment therapies at
critical limb ischemia treatment market
Table of Contents
Get in touch with our Business executive at
Healthcare Due Diligence Services
Related Reports
Critical Limb Ischemia Epidemiology
Critical Limb Ischemia Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted critical limb ischemia epidemiology in the 7MM.
Critical Limb Ischemia Pipeline
Critical Limb IschemiaIschemia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key critical limb ischemia companies involved are
Pluristem Therapeutics, Reven Pharmaceuticals, Inc., New Beta Innovation Limited, among others.
Critical Limb Ischemia Market
Critical Limb Ischemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key companies such as
Boston Scientific Corporation, AnGes, Inc, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, among others.
Peripheral Arterial Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted peripheral arterial disease epidemiology in the 7MM.
Peripheral Arterial Disease Pipeline
Peripheral Arterial Disease Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products. The key companies are
NovoNordisk, Takeda, Mercator MedSystems, Inc., among others.
Peripheral Arterial Disease Market
Peripheral Arterial Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, and market barriers. The key companies are
NovoNordisk, Takeda, Mercator MedSystems, Inc., among others.
Other Trending Reports
Degenerative Disc Disease (DDD) Market
"Degenerative Disc Disease (DDD) Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the degenerative disc disease market size, share, and trends in the 7MM. Some of the key companies in the degenerative disc disease market are
DiscGenics, Kuros Biosciences, Mesoblast, Ankasa Therapeutics, and others.
Periodontal Disease Market
"Periodontal Disease Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the periodontal disease market size, share, and trends in the 7MM. Some of the key companies in the periodontal disease market are
D and D Pharmatech, Amyndas Pharmaceuticals, AngioLab, Denteric, Dexcel Pharma Technologies, Yuhan Corporation, and others.
IgG4-related Disease Market
"IgG4-Related Disease Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the IgG4-related disease market size, share, and trends in 7MM. Some of the key companies in the IgG4-related disease market are
Bristol-Myers Squibb, Xencor, Principia Biopharma, Viela Bio, Horizon Therapeutics, and others.
"Nicotine Addiction Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the nicotine addiction market size, share, and trends in the 7MM. Some of the key companies in the nicotine addiction therapeutics market include
Axsome Therapeutics, Achieve Life Sciences, Novo Nordisk, and others.
Hairy Cell Leukemia (HCL) Market
"Hairy Cell Leukemia (HCL) Market" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the hairy cell leukemia (HCL) market size, share, and trends in the 7MM. Some of the key companies in the hairy cell leukemia (HCL) therapeutics market include
AstraZeneca, Janssen, Merck, Pharmacyclics, Johnson and Johnson, Roche, Innate Pharma, and others.
Hypereosinophilic Syndrome Market
"Hypereosinophilic Syndrome Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the hypereosinophilic syndrome market size, share, and trends in 7MM. Some key companies in the hypereosinophilic syndrome market include
AstraZeneca, GlaxoSmithKline, Knopp Biosciences, and others.
Related Healthcare Blogs
Upcoming Cardiovascular Diseases Drugs
Key Companies in the Cardiology Segment
About DelveInsight
DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Contact Us
[email protected]
+1(919)321-6187
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.